awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q30995889-39D5107A-BE80-4727-B0B9-13D7C785C1B9
Q30995889-39D5107A-BE80-4727-B0B9-13D7C785C1B9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30995889-39D5107A-BE80-4727-B0B9-13D7C785C1B9
The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
P2860
Q30995889-39D5107A-BE80-4727-B0B9-13D7C785C1B9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30995889-39D5107A-BE80-4727-B0B9-13D7C785C1B9
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0ee3cef18176060ca226ec59e08b530535c869d6
P2860
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.